Stockreport

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius Pharmaceuticals, Inc.  (CTXR) 
NASDAQ:AMEX Investor Relations: ir.citiuspharma.com
PDF CRANFORD, N.J., April 1, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on deve [Read more]